SCHEMBL3289203

SCHEMBL3289203

COc1cc(OC)c(C(=O)N[C@H]2[C@H](c3ccc(Cl)cc3)C2(C)C)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 3/20 0.43
KMT2A Q03164 2/20 0.43
NPC1 O15118 3/20 0.41
RAB9A P51151 2/20 0.41
HTR4 Q13639 2/20 0.41
MEN1 O00255 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
HPGD P15428 1/20 0.40
LMNA P02545 2/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
ALOX15 P16050 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
POLB P06746 1/20 0.39
CASP3 P42574 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3289194 1.00 KDM4E (0.46) KDM4ENPSR1ALDH1A1KMT2ANPC1
SCHEMBL3289196 1.00 KDM4E (0.46) KDM4ENPSR1ALDH1A1KMT2ANPC1
SCHEMBL3286762 0.93 KMT2A (0.41) KDM4ENPSR1ALDH1A1KMT2ANPC1
SCHEMBL3286759 0.93 KMT2A (0.41) KDM4ENPSR1ALDH1A1KMT2ANPC1
SCHEMBL3286767 0.93 KMT2A (0.41) KDM4ENPSR1ALDH1A1KMT2ANPC1
SCHEMBL3290949 0.93 KMT2A (0.44) KDM4ENPSR1ALDH1A1KMT2ANPC1
SCHEMBL3290945 0.93 KMT2A (0.44) KDM4ENPSR1ALDH1A1KMT2ANPC1
SCHEMBL3290953 0.93 KMT2A (0.44) KDM4ENPSR1ALDH1A1KMT2ANPC1
SCHEMBL3295195 0.92 KDM4E (0.47) KDM4EALDH1A1KMT2ANPC1RAB9A
SCHEMBL3295193 0.92 KDM4E (0.47) KDM4EALDH1A1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723391-B2 Cyclopropyl aryl amide derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2010-05-25 US claimed
EP-2207540-B1 CYCLOPROPYL ARYL AMIDE DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2014-02-26 EP disclosed
US-7723391-B2 Cyclopropyl aryl amide derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2010-05-25 US disclosed
US-20090093525-A1 Cyclopropyl aryl amide derivatives and uses thereof ROCHE PALO ALTO LLC 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093525-A1 Cyclopropyl aryl amide derivatives and uses thereof AR, ADRA2A, ADRA1A KDM4E 3029/4885NPSR1 262/4885ALDH1A1 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.